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Abstract
CXCL5 is a proangiogenic CXC-type chemokine that is an inflammatory mediator and a powerful attractant for
granulocytic immune cells. Unlike many other chemokines, CXCL5 is secreted by both immune (neutrophil, mono-
cyte, and macrophage) and nonimmune (epithelial, endothelial, and fibroblastic) cell types. The current study was
intended to determine which of these cell types express CXCL5 in normal and malignant human prostatic tissues,
whether expression levels correlated with malignancy and whether CXCL5 stimulated biologic effects consistent
with a benign or malignant prostate epithelial phenotype. The results of these studies show that CXCL5 protein
expression levels are concordant with prostate tumor progression, are highly associated with inflammatory infil-
trate, and are frequently detected in the lumens of both benign and malignant prostate glands. Exogenous admin-
istration of CXCL5 stimulates cellular proliferation and gene transcription in both nontransformed and transformed
prostate epithelial cells and induces highly aggressive prostate cancer cells to invade through synthetic basement
membrane in vitro. These findings suggest that the inflammatory mediator, CXCL5, may play multiple roles in the
etiology of both benign and malignant proliferative diseases in the prostate.
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Introduction
The American Cancer Society estimates that there will be nearly
219,000 newly diagnosed cases of prostate cancer in the United
States in 2007 and that an estimated 27,000 patients, or more than
10% of those diagnosed with prostate cancer, will die of this disease.
It is also estimated that prostate cancer alone will account for almost
30% of cancer incidents in American men and almost 10% of cancer
deaths. Although deaths due to prostate cancer have declined over
the past decades, it is still the most commonly diagnosed cancer
and accounts for the second highest death rate from cancer among
American men [1]. Clearly, a better understanding of the biology of
prostate cancer initiation and progression that would facilitate the
development of strategies for the successful prevention or therapeutic
intervention of this common malignancy is needed.
Although successful interventional therapeutic strategies for prostate
cancer have hinged on hormonal ablation therapies, recent studies have
shown that growth factors other than steroid hormones play key roles
in the development and progression of prostate cancer. Among these
molecules are a large class of immunomodulator proteins termed che-
mokines. Chemokines are soluble mediators involved in angiogenesis,
cellular growth control, cellular motility, wound healing, and inflamma-
tory responses [2]. Although extensively studied as part of the immune
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system, chemokines have recently been investigated as possible media-
tors of mammalian tumor development and progression. Our labora-
tory has shown that the CXC-type chemokine, CXCL12, is secreted at
subnanomolar quantities by aging prostate stroma and stimulates both
a proliferative and transcriptional response from both nontransformed
and transformed prostate epithelial cells [3,4]. Several other laboratories
have shown that stromally secreted CXCL12 stimulates prostate cancer
cells to become motile and invade through both synthetic basement
membrane and endothelial cell barriers in vitro, and promotes prostate
tumor growth and metastasis in vivo [5–8].
More recently, another CXC-type chemokine, CXCL5, has been
the focus of studies examining the role(s) of chemokines in tumori-
genesis. Like other chemokines that recognize and bind the G-
protein–coupled receptor CXCR2, CXCL5 is proangiogenic and is
a powerful attractant for granulocytic immune cells. Unlike many
other chemokines, however, CXCL5 is secreted by several cell types,
including epithelial cells, endothelial cells, fibroblasts, neutrophils,
monocytes, and macrophages [2,9]. Studies examining the expression
of CXCL5 in human tumors and tumor cells in vitro have reported
that CXCL5 transcripts are significantly upregulated in sporadic en-
dometrioid endometrial adenocarcinomas compared to normal endo-
metrium [10]. CXCL5 transcript and secreted protein have also been
observed as significantly upregulated in cells derived from metastatic
compared to primary head and neck squamous cell carcinomas, and
RNA interference of the CXCL5 transcript reduced the ability of
head and neck squamous carcinoma cells to migrate and invade
through the Matrigel in vitro [11,12]. Studies by Park et al. [13] have
shown that CXCL5 protein overexpression was associated with late-
stage gastric cancer and high N stage, suggesting a role for CXCL5 in
the progression of gastric cancer, specifically in lymph node metasta-
sis. The current study was intended to investigate whether CXCL5
was expressed concordantly with prostate tumor progression, and
whether CXCL5 could stimulate phenotypic responses in prostate
epithelial cells consistent with malignant progression.
Methods
Construction of Tissue Microarray and Immunohistochemistry
A tissue microarray (TMA) was constructed from 99 prostate tis-
sues including benign prostate, localized prostate cancer, and ad-
vanced hormone refractory metastatic prostate cancer. The radical
prostatectomy series is part of the University of Michigan Prostate
Cancer Specialized Program of Research Excellence (SPORE) Tissue
Core. Metastatic prostate cancer cases were a part of the Rapid Autopsy
series at the University of Michigan and supported by SPORE. All
patients provided written informed consent, and this study was ap-
proved by the Institutional Review Board at the University of Michigan
Medical School.
Immunostaining was performed on the TMA using standard avidin-
biotin complex techniques and a mouse monoclonal antibody against
CXCL5. The slide was pretreated by microwaving in Tris buffer, pH
9.0, for antigen retrieval. The TMA was then incubated overnight
with primary CXCL5 antibody (Human CXCL5/ENA-78 MAb
clone 33160; R&D Systems, Minneapolis, MN) at a dilution of
1:25. CXCL5 expression was scored in a blinded fashion as negative
(score = 1), weak (score = 2), moderate (score = 3), or strong (score =
4) based on the intensity of staining and the percentage of cells ex-
hibiting that staining intensity. Product scores (intensity × percentage
values) were calculated for all tissue cores, and the median product
scores were determined for specific tissue types (benign glands, ma-
lignant glands, and metastases). These values were used in subse-
quent statistical analyses.
Cell Cultures
N15C6 and BPH-1 cells are nontransformed prostate epithelial cells;
they grow continuously in culture but do not form colonies in soft agar
or tumors in immunocompromised mice [14–16]. Both cell lines were
maintained in 5% HIE media (Ham’s F12; Mediatech Inc., Herndon,
VA) with 5% FBS (Life Technologies, Inc.), 5 μg/ml insulin, 10 ng/ml
epidermal growth factor, 1 μg/ml hydrocortisone (Sigma Chemical Co.,
St. Louis, MO), or in defined serum-free (SF) media supplemented to
5 mM ethanolamine (Sigma Aldrich), 10 mMHEPES (Sigma Aldrich),
5 μg/μl transferrin (Sigma Aldrich), 10 μM 3,3′,5-triiodo-l-thyronine
(Sigma Aldrich), 50 μM sodium selenite (Sigma Aldrich), 0.1% BSA
(JRH Biosciences, Lenexa, KS), 0.05 mg/ml gentamycin (Invitrogen,
Carlsbad, CA), and 0.5 μg/ml fungizone (Cambrex Bioscience,
Walkersville, MD). The androgen-sensitive LNCaP and 22Rv1 and
the androgen-insensitive PC3-transformed prostate epithelial cell
lines were maintained in 10% RPMI media or SF RPMI (0.1%
BSA) and in antibiotics as described previously [17–19].
ELISA Assays
Semiconfluent cells were grown in SF media over a 48-hour period.
The resulting conditioned media was collected, serially concentrated
using centrifugal filters (Centriplus; Millipore, Billerica, MA) with a
3-kDa molecular weight cutoff, and assessed using the R&D Sys-
tems DuoSet kit for Human CXCL5/ENA-78. All reactions were per-
formed in duplicate, and the resulting values were averaged [3].
Cellular Growth Assays
Cellular proliferation, after plating cells at a density of 1000 cells/
well, was assessed in triplicate in multiwell plates by counting cells
after 24 and 96 hours of incubation as described previously [14].
To assess the effects of exogenous CXCL5 on cellular proliferation,
recombinant human CXCL5 (254-X; R&D Systems) was added at
the desired concentration in SF media (alone for control) to each
well. The cells were refed at 24 hours of growth period and counted
at 24 and 96 hours of growth period. Averages and standard devia-
tions of the cell number were calculated for each time point under
each media condition to permit statistical analysis. For the antibody
blockade experiments, 10,000 cells/well were plated in triplicate in
24-well dishes and preincubated with mouse anti–human CXCR2
(AHR1532X; Invitrogen) or mouse anti–human CXCR4 (555971;
BD Pharmingen, San Diego, CA) at 1 μg/ml for 1 hour before add-
ing CXCL5. Cells were maintained in media containing appropriate
antibodies for the entirety of the experiment and were counted at 24
and 96 hours of growth.
For the measurement of apoptosis, nucleosomal DNA was assayed
using Cell Death Detection ELISA kit (Roche Diagnostics, Indianapolis,
IN). Cells were seeded into six-well plates and grown overnight; and trip-
licate wells were changed to SF media alone or SF media supplemented
with 10 pM CXCL5 for N15C6 cells or 100 pM CXCL5 for LNCaP
cells. Cells were trypsinized, collected, washed, and counted at 0, 24, 48,
and 72 hours, respectively. Twenty thousand cells were extracted with
200 μl of incubation buffer for 30 minutes at room temperature and
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then centrifuged, after which the supernatant was subjected to ELISA
according to the manufacturer’s protocols (Roche Diagnostics). The
fraction of cells exhibiting apoptosis was calculated as the difference in
absorbance measured at 405 nm and at the reference wavelength of
490 nm after adjusting for background absorbance at both wavelengths.
Averages and standard deviations were calculated for each time point
under each condition to permit statistical analysis.
Invasion Assays
The ability to invade through the synthetic basement membrane
was measured by plating 15,000 cells/well onto Matrigel-coated
membranes in duplicate using 24-well BD Matrigel Invasion Cham-
bers (Becton-Dickinson, Franklin Lakes, NJ). Cells were plated in
complete media and left untreated or pretreated either with 1 μg/
ml anti-CXCR2 (#CMC203; Cell Sciences, Canton, MA) or with
1 μg/ml anti-CXCR4 (555971; BD Pharmingen) for 2 hours and
were then exposed to complete media only or to 20 nM CXCL5
as a chemoattractant added to the companion plate. After 24 hours
of incubation, the upper surface of the membranes was scrubbed to
remove noninvasive cells, and the cells that had invaded to the lower
surface of the Matrigel-coated membranes or to the bottom of the
companion plate were fixed, stained, and counted. The number of
invaded cells was calculated as the average number of cells present
on the lower surface of the Matrigel-coated membrane and on the
companion plate counted over four low-power (magnification,
×10) microscopic fields per membrane over both wells per experi-
mental condition. Fold invasion was calculated as the number of in-
vaded cells counted under experimental conditions divided by the
number of invaded cells counted under control conditions, with rela-
tive invasion under control conditions equivalent to one-fold.
Western Blot and Protein Analyses
Cells were lysed, proteins were resolved by electrophoresis, and
electroblot analysis was carried out as described previously [3,4]. Pro-
teins were detected using antibodies against CXCR2 (#CMC203;
Cell Sciences), phospho–extracellular signal–regulated kinase (ERK)
1/2 (#9101; Cell Signaling, Danvers, MA), total ERK 1/2 (#9102;
Cell Signaling), phospho-p65 (#100-401-264; Rockland Immuno-
chemicals), total p65 (#100-4165; Rockland Immunochemicals), sig-
nal transducer and activator of transcription-3 (STAT3) (#9139; Cell
Signaling), phospho-STAT3 (#9138; Cell Signaling), β-actin (#sc-
1615; Santa Cruz Biotechnology, Santa Cruz, CA), or tubulin
(#DM1A; Millipore) in conjunction with an enhanced chemilumi-
nescent (ECL) detection system (Millipore). Secondary antibodies
included goat anti-rabbit (#7074; Cell Signaling) and goat anti-
mouse (#sc-2005; Santa Cruz Biotechnology), and both were used
at a concentration of 1:5000. Immunoblots shown are representative
of triplicate experiments. Densitometric quantitation of immunoblot
films was accomplished by scanning the original films and converting
the .tiff files to grayscale. Images were inverted, and mean band inten-
sities were measured using ImageJ (www.nih.gov). The mean intensity
of adjacent background was also measured for each band and was sub-
tracted from band intensity.
Quantitative Real-Time Polymerase Chain Reaction
All quantitative real-time assays were conducted as previously de-
scribed using a real-time polymerase chain reaction (PCR) system
(7900 HT; Applied Biosystems, Foster City, CA) and reagents [6].
Cells were grown to 70% confluence in 60-mm dishes before
RNA purification using the Trizol reagent (Invitrogen Life Technol-
ogies). For all experiments, 1 μg of RNA was reverse-transcribed by
using Superscript III reverse transcriptase (Invitrogen). The resulting
cDNA was diluted to 1:100. Real-time PCR was performed by using
Assays-on-Demand (Applied Biosystems) according to the manufac-
turer’s instructions. Reactions were performed in triplicate, including
no-template controls and an endogenous control probe, RPLP0
(ribosomal protein, large, P0), to assess template concentration. Cycle
numbers to threshold were calculated by subtracting averaged con-
trol from averaged experimental values at each time point, and Fold
Gene Expression was calculated by raising these values exponential
to the base 2. Fold transcript values obtained at time 0 are set and
normalized to one-fold to permit comparison with subsequent time
points. Carboxyfluorescein (FAM)-conjugated, gene-specific assays
were Hs00152928_m1 for the early growth response 1 (EGR1) gene
and Hs99999902_m1 for the control, RPLP0.
Statistical Analysis
Densitometric data from multiple experiments were averaged and
standard deviations were calculated for graphical depiction and statis-
tical analysis. Similarities and differences between median-product
score distributions between the different histologic subtypes repre-
sented on the tissue microarray data were evaluated using Kruskal-
Wallis and Wilcoxon rank sum tests. All other data were assessed
by t test or by analysis of variance, with P < .05 considered statisti-
cally significant.
Results
CXCL5 Protein Expression Levels Are Significantly Elevated
in Primary and Metastatic Prostate Tumors
CXCL5 protein expression in human prostate tissues was evaluated
by immunohistochemical analysis of a tissue microarray compris-
ing 360 cores obtained from 99 tissue samples, of which 226 cores
representing 83 separate tissue samples could be evaluated. These in-
cluded benign glands (n = 32 tissues, 76 cores), primary prostate tu-
mors (PCa; n = 35 tissues, 84 cores), metastatic prostate tumors
(METs, n = 11 tissues, 29 cores), and miscellaneous other histologic
subtypes [benign prostatic hyperplasia, n = 7 tissues, 15 cores; pros-
tatic intraepithelial neoplasia (PIN), n = 5 tissues, 8 cores; prostatic
atrophy, n = 9 tissues, 12 cores; prostatic inflammatory atrophy, n = 2
tissues, 3 cores]. The CXCL5 protein exhibited diffuse cytoplasmic
cellular localization by immunostaining, which was largely confined
to epithelial cell types in both benign and malignant glands. As
shown in Figure 1, CXCL5 immunostaining was significantly higher
in PCa compared to benign glands (P < .0001) and was significantly
higher in METs compared to PCa (P = .05) or benign glands (P =
.0002). CXCL5 immunostaining was also significantly higher in PIN
than benign glands (P = .0008), although only five PIN lesions that
could be evaluated were present on the TMA (not shown). Taken
together, these data show that CXCL5 protein expression levels in-
creased concordantly with prostate tumor progression. Further evalua-
tion of CXCL5 protein expression levels among PCa revealed a
trend toward higher expression levels in tumors exhibiting com-
bined Gleason scores of 7 or greater (n = 25) compared to those with
combined Gleason scores of 6 or less (n = 8) (P = .055) (Figure 1, B
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and C ); some of these cancer areas were associated with stromal in-
flammation (Figure 1E ).
CXCL5 immunostaining was associated with stromal inflamma-
tion in 50% (6 of 12) of cores containing atrophic glands and
100% (3 of 3) of cores containing prostatic inflammatory atrophy
lesions. CXCL5 protein immunostaining was also detected in the
luminal space of glands histologically characterized as benign (6 of
75 cores, 8.0%), hyperplastic (4 of 5 cores, 27%), PIN (2 of 8 cores,
25%), or malignant glands (6 of 84 cores, 7%), consistent with active
secretion of CXCL5 into the lumen (Figure 1F ). It should be noted
that cores from two different cases containing hyperplastic glands
demonstrated both luminal and inflammation-associated CXCL5
staining affecting the same glands.
CXCL5 Induces a Proliferative Response in Prostate Cancer
Cells In Vitro
Because the studies on TMA demonstrated that CXCL5 protein
expression levels increased concordantly with prostate tumor progres-
sion, we wished to investigate whether CXCL5 promoted a pheno-
typic response consistent with prostate tumor development and/or
progression in vitro. To accomplish this, we first determined whether
nontransformed N15C6 and BPH-1, or transformed LNCaP and
PC3, prostate epithelial cells expressed CXCR2, the receptor for
CXCL5, or endogenously secreted CXCL5. Western blot analysis
of protein lysates prepared from nontransformed BPH-1 and
N15C6 cells, and transformed LNCaP and PC3 cells, immuno-
blotted and probed with an antibody against CXCR2 revealed a band
corresponding to a molecular weight of 40 kDa, consistent with that
of CXCR2. Although the quality of the antibody precluded precise
quantitation of the amount of CXCR2 protein, the immunoblot
data shows that the relative amount of CXCR2 protein expressed
was variable between cell lines (Figure 2A). ELISA of media con-
ditioned by the same four cell lines showed that LNCaP secreted
very low levels of CXCL5, on the order of less than 10 pg/ml into
the media. N15C6 cells secreted 10-fold higher levels of CXCL5
into the media than LNCaP, and both BPH-1 and PC3 cells secreted
Figure 1. CXCL5 protein expression is concordant with prostate cancer progression. Shown are representative panels from a hematox-
ylin and eosin–stained, high-density tissue microarray probed with antibody against CXCL5, as follows: (A) Benign glands demonstrating
weak staining. (B) PCa (Gleason sum 3 + 3) demonstrating weak staining. (C) PCa (Gleason sum 4 + 4) demonstrating moderate to
strong staining. (D) Hormone refractory METs demonstrating strong staining. (E) PCa demonstrating moderate to strong staining asso-
ciated with stromal inflammatory component (yellow arrows point to areas of inflammation). (F) Benign glands demonstrating strongly
staining luminal secretions (black arrows). Original magnifications, ×100. Panel E has been enlarged further, ×4, to illustrate the area of
inflammatory infiltrate concomitant with CXCL5 protein expression. (G) Boxplot depicting median product score distributions of protein
expression levels for benign glands, malignant glands from PCa, and malignant areas from METs and P values associated with the
statistical evaluation of these distributions.
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approximately 100-fold higher levels of CXCL5 into the media than
LNCaP (Figure 2B). Taken together, these results showed that the
levels of CXCR2 and CXCL5 protein expressed by the four prostate
epithelial cell lines examined was variable and did not appear to be
directly related to whether the cells were phenotypically transformed
or nontransformed.
Because the cell lines tested for endogenous CXCL5 secretion were
immortalized and highly proliferative, and expressed the appropriate
receptor for CXCL5, we tested whether exogenously administered
CXCL5 could stimulate a proliferative response in these cells. For
these experiments, nontransformed (N15C6 and BPH-1), androgen-
responsive transformed (22Rv1 and LNCaP) or androgen-insensitive
transformed (PC3) prostate epithelial cells were seeded in triplicate,
then grown for 3 days in SF media or the same media supplemented
with increasing doses of CXCL5. These studies showed that CXCL5
initiates a moderate, but reproducible and statistically significant (P <
.05), proliferative response in N15C6, BPH-1, LNCaP, and 22Rv1,
but not PC3, prostate cancer cells in vitro (Figure 3). Both N15C6
and BPH-1 cells proliferated to significantly higher levels in response
to almost all concentrations of CXCL5 tested compared to growth
in SF media alone (Figure 3). LNCaP and 22Rv1 cells responded
similarly to each other and proliferated significantly in response to
only very low levels (1 or 10 pM) of CXCL5. Higher levels of CXCL5,
e.g., 100 pM and 1 nM, were actually growth-suppressive in these
cells (Figure 3).
The specificity of the CXCL5-mediated proliferative response in
the nontransformed N15C6 and BPH-1 cells was next tested
through antibody blockade experiments. For these studies, the cells
were pretreated with an antibody against the CXCL5-specific recep-
tor, CXCR2, or that of an unrelated chemokine receptor, CXCR4.
The results of these experiments showed that pretreatment with the
antibody against the CXCL5-specific receptor, CXCR2, significantly
(P < .001) ablated the ability of CXCL5 to stimulate proliferation in
both cell lines. However, pretreatment with an antibody directed
against the unrelated chemokine receptor, CXCR4, did not ablate
the CXCL5-mediated proliferative response in either cell line (Fig-
ure 4A). Additional experiments showed that the fraction of cells ex-
hibiting apoptosis was similar in untreated cells and in those treated
with CXCL5 for both nontransformed N15C6 and transformed
Figure 2. Nontransformed and transformed prostate epithelial
cells express the CXCL5 receptor and endogenously secrete
CXCL5. (A) Immunoblot analysis of protein lysates prepared from
transformed PC3 and LNCaP, and nontransformed N15C6 and
BPH-1 prostate epithelial cells probed with antibodies specific
for the CXCL5 receptor, CXCR2, and loading control, β-actin. Pri-
mary antibody concentrations used were 1:1000 for CXCR2 and
1:5000 for β-actin. (B) Protein levels (pg/ml) of CXCL5 present in
media conditioned by transformed LNCaP and PC3 or nontrans-
formed N15C6 or BPH-1 cells prostate epithelial cells were deter-
mined by ELISA. The graph shows the pg/ml CXCL5 detected
plotted on a logarithmic scale (y axis).
Figure 3. Prostate epithelial cells proliferate in response to CXCL5.
Nontransformed N15C6 or BPH-1 cells, androgen-sensitive trans-
formed LNCaP or 22Rv1, or androgen-insensitive transformed PC3
cells, were plated at 1000 cells/well in triplicate in SF media, har-
vested, and counted 24 or 96 hours later. The mean and standard
deviation (error bars) of cell numbers obtained at each time point
for growth in SF media is indicated by white diamonds, in SF
media supplemented to 1 pM CXCL5 by black diamonds, to 10 pM
CXCL5 by white triangles, to 100 pM CXCL5 by black triangles, and
to 1 nM CXCL5 by white squares. The experiments shown are repre-
sentative of replicate proliferation assays.
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LNCaP cells (Figure 4B). Taken together, these studies showed that
the observed CXCL5-mediated proliferative response was depen-
dent on interactions with the G-protein–coupled receptor, CXCR2,
which specifically recognizes this chemokine. Moreover, these studies
showed that CXCL5 promoted a pro-proliferative, rather than an
antiapoptotic, response in prostate epithelial cells.
CXCL5 Stimulates Prostate Cancer Cell Migration and
Invasion In Vitro
Several studies have shown that the CXC-type chemokine,
CXCL12, stimulates the migration and invasion of prostate cancer cells
in vitro and in vivo [5–8] and that migration in vitro was observed using
a concentration of CXCL12 in the 10 to 20 nM range. Therefore, we
examined whether CXCL5 could also stimulate acquisition of an in-
vasive phenotype by prostate cancer cells. Using a modified Boyden
chamber assay, 15,000 nontransformed N15C6 or transformed PC3
cells were plated onto Matrigel-coated membranes (upper wells) and
were exposed to complete media or complete media supplemented
with 20 nM CXCL5 for 24 hours. After 24 hours, the cells that mi-
grated and invaded through the Matrigel were stained and counted. As
seen in Figure 4C, significantly more PC3 cells migrated through the
Matrigel in response to CXCL5 than to the vehicle (*P < .05). In con-
trast, N15C6 cells did not migrate through the Matrigel in response
to CXCL5. To test the specificity of the CXCL5-mediated invasive
Figure 4. CXCL5-stimulated proliferative and invasive responses. (A) N15C6 (light gray bars) or BPH-1 (dark gray bars) nontransformed
prostate epithelial cells proliferated to significantly higher levels when grown for 72 hours in SF media supplemented with 10 pM CXCL5
than those grown in SF alone (*P < .001). Preincubation of the cells for 1 hour with 1 μg/ml antibody against CXCR2, the receptor for
CXCL5, followed by supplementation with CXCL5 and maintenance of growth in CXCL5 + anti-CXCR2–containing media significantly
ablated the proliferative response (#P < .001). In contrast, cellular growth after preincubation with an antibody against an unrelated
chemokine receptor, CXCR4, followed by supplementation with CXCL5 and maintenance of growth in CXCL5 + anti-CXCR4–containing
media was similar to that observed for non–pretreated cells grown in CXCL5-supplemented media and was significantly higher than that
in SF alone (*P < .001). All data are shown normalized to growth in unsupplemented SF, which was set at one-fold. (B) N15C6 (LEFT) or
LNCaP (RIGHT) cells were grown in SF media (untreated, UnT) or SF media supplemented with 10 pM CXCL5 for N15C6 or 100 pM
CXCL5 for LNCaP (treated, T) for the times indicated. The cells were then harvested and assessed for nucleosomal DNA fragmentation.
The fraction of cells exhibiting apoptosis plotted on the y axis was calculated as the difference in absorbance measured at 405 nm and at
the reference wavelength of 490 nm after adjusting for background absorbance at both wavelengths. No significant differences in the
fraction of cells exhibiting apoptosis were observed between treated and untreated cells at any time point, demonstrating that CXCL5
does not promote antiapoptotic responses in these cells. (C) Fifteen thousand each of N15C6 (black bars) or PC3 (gray bars) cells were
plated onto Matrigel-coated membranes and were exposed to complete media or complete media supplemented with 20 nM CXCL5 for
24 hours. After 24 hours, the cells that migrated and invaded through the Matrigel were stained and counted. N15C6 cells did not
demonstrate an invasive response to treatment with CXCL5. However, approximately six-fold more PC3 cells migrated through the
synthetic basement membrane, Matrigel, in response to 20 nM CXCL5 compared to vehicle (control, set at one-fold) (*P < .05). PC3
cell invasion through the Matrigel in response to CXCL5 was significantly inhibited by pretreatment with 1 μg/ml blocking antibody (anti-
CXCR2) (#P < .05) but not by pretreatment with nonspecific antibody (anti-CXCR4) (*P < .05).
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response, PC3 cells were pretreated for 2 hours with 1 μg/ml block-
ing antibody (anti-CXCR2) or nonspecific antibody (anti-CXCR4)
in the bottom wells for 12 hours, then treated with vehicle or
20 nM CXCL5. These experiments showed that significantly more
PC3 cells migrated through the Matrigel in response to CXCL5 than
to the vehicle (*P < .05) and that this activity was blocked by an
antibody against the receptor to CXCL5, CXCR2, but not against
the receptor to CXCL12, CXCR4 (Figure 4C ). Thus, transformed
PC3 prostate epithelial cells demonstrated a robust and specific
migratory/invasive response to CXCL5 in vitro. In contrast, non-
transformed N15C6 cells did not migrate or invade through the
Matrigel in response to CXCL5.
CXCL5 Activates Both Mitogen-Activated Protein Kinase
and Phosphoinositide 3-Kinase Signaling in Prostate
Epithelial Cells
We and others have shown that another CXC-type chemokine,
CXCL12, interacts with its primary receptor, CXCR4, to activate
downstream signaling events involving the mitogen-activated protein
kinase (MAPK) and/or phosphoinositide 3-kinase (PI3K), and/or
Janus kinases/signal transducers and activators of transcription (JAK/
STAT) pathways in prostate epithelial cells [3,4]. To begin to test
whether CXCL5 activated similar pathways associated with prostate
epithelial cellular proliferation or invasion, N15C6 or LNCaP cells
were treated with increasing doses of CXCL5 and assessed for acti-
vation of ERK 1/2 (MAPK pathway), the p65 subunit of nuclear
factor–kappa B (NF-κB; PI3K pathway), or STAT3 (JAK/STAT
pathway). As seen in Figure 5, nontransformed N15C6 cells rapidly
and transiently phosphorylated ERK 1/2 and STAT3 when treated
with either subnanomolar (10 or 100 pM) or nanomolar (1 nM) lev-
els of CXCL5, whereas NF-κB subunit activation was evident only
after treatment with 1 nM CXCL5. Transformed LNCaP cells rap-
idly and transiently phosphorylated both ERK 1/2 and the p65 sub-
unit of NF-κB on treatment with subnanomolar (10 or 100 pM)
levels of CXCL5 (Figure 6). However, activation of either ERK 1/
2 or NF-κB was not evident in LNCaP cells treated with nanomolar
levels of CXCL5 (Figure 6), and activation of STAT3 was not ob-
served in LNCaP cells treated with either subnanomolar or nanomo-
lar levels of CXCL5 (not shown).
CXCL5 Stimulates EGR1 Gene Transcription
We have recently shown that another CXC-type chemokine,
CXCL12, stimulates a complex and robust transcriptional response
in both nontransformed N15C6 and transformed LNCaP prostate
Figure 5. CXCL5 activates MAPK signaling in nontransformed N15C6 prostate epithelial cells. Nontransformed N15C6 cells rapidly and
transiently phosphorylated ERK 1/2 and STAT3 when treated with either subnanomolar (10 or 100 pM) or nanomolar (1 nM) levels of
CXCL5, whereas NF-κB subunit activation was evident only after treatment with 1 nM CXCL5. Primary antibody concentrations used
were 1:500 for phospho-ERK, 1:500 for phospho-65 (NF-κB), 1:1000 for phospho-STAT3, 1:1000 for total ERK, 1:1000 for total p65, and
1:2000 for total STAT3. A total of 20 μg of protein lysate was electrophoresed per well. Immunoblots are shown on the left, and
corresponding densitometric evaluations of the same blots are shown on the right. Phosphorylation relative to total protein quantitated
from the immunoblot is shown in the densitometric plots as phospho/total protein.
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epithelial cells [5]. In particular, CXCL12 activated transcription of
EGR1, which encodes a C2H2-type zinc-finger protein induced by
mitogenic stimulation and shown to stimulate tumor cell growth, play
a role in tumor progression, and stimulate angiogenesis and improved
survival of tumor cells [4,20]. Therefore, we investigated whether
CXCL5 stimulated a transcriptional response in nontransformed or
transformed prostate epithelial cells. As shown in Figure 7, nontrans-
formed N15C6 cells treated with subnanomolar levels (1-100 pM)
Figure 6. CXCL5 activates both MAPK and PI3K signaling in transformed LNCaP prostate epithelial cells. Transformed LNCaP cells rapidly
and transiently phosphorylated both ERK 1/2 and the p65 subunit of NF-κB on treatment with subnanomolar (10 or 100 pM) levels of CXCL5.
Immunoblots are shown in the top panel, and corresponding densitometric evaluations of the same blots are shown in the bottom panel.
Phosphorylation relative to total protein quantitated from the immunoblot is shown in the densitometric plots as phospho/total protein. A
total of 100 μg of protein lysate was electrophoresed per well. Primary antibody concentrations used were as described for Figure 5.
Figure 7. CXCL5 stimulates a transcriptional response in both nontransformed and transformed prostate epithelial cells. Quantitative
real-time PCR of RNA purified from N15C6 cells (left) or LNCaP cells (right) treated with subnanomolar CXCL5 as shown demonstrates
rapid and robust transcription of the EGR1 gene significantly higher than levels obtained at time 0 (set at one-fold) (*P < .05). Data
shown are averaged from three or more separate experiments per time point per concentration of CXCL5 examined.
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CXCL5 rapidly accumulated four- to eight-fold more EGR1 transcript
than vehicle-treated cells. Similarly treated transformed LNCaP cells
accumulated two- to three-fold more EGR1 transcript than vehicle-
treated cells, but only at the lowest CXCL5 concentration (10 pM) tested.
Discussion
The studies reported here are the first to demonstrate that CXCL5
protein expression increases concordantly with prostate tumor pro-
gression. Moreover, CXCL5 protein expression was observed as
equivalently more abundant in PIN lesions (P < .0008) and in pri-
mary tumors (P < .0001) compared to benign glands, suggesting that
CXCL5 protein upregulation is an early event during prostate tumor-
igenesis. These findings parallel those reported for the CXCL5 recep-
tor, CXCR2, which was also characterized by higher protein
expression levels in malignant prostate glands and high-grade PIN
lesions compared to benign glands [21]. The observation that
CXCL5 expression was slightly elevated in metastatic tumors com-
pared to primary tumors (P = .05) also implies that expression of this
protein remains high, and may increase, during prostate cancer me-
tastasis. Studies by Park et al. [13] have shown that CXCL5 protein
overexpression was associated with late-stage gastric cancer and high
N stage, suggesting a role for CXCL5 in the progression of gastric
cancer, specifically in lymph node metastasis. Taken together, these
data indicate that CXCL5 expression increases concordantly with
tumor progression in prostate and other cancers.
CXCL5 is a member of a proangiogenic subgroup of the CXC-
type chemokine family of small, secreted proteins [2,9]. Luminal
staining suggestive of active secretion of CXCL5 protein was ob-
served in approximately 10% to 25% of tissue cores examined con-
taining benign, hyperplastic, PIN, or malignant glands. Other studies
have shown that concentrations of CXCL5 in peritoneal fluid are
markedly elevated in women with severe endometriosis, a disease
characterized by ectopic proliferation of highly vascularized endome-
trial tissue [10,22]. Miyazaki et al. [11] recently reported that cells
derived from a gastric cancer lymph node metastasis, but not from
a primary tumor from the same patient, actively secreted CXCL5.
Data reported in this study show that both nontransformed and
transformed prostate epithelial cells secrete varying levels of CXCL5
and express CXCR2, the CXCL5 receptor. Taken together, these stud-
ies all associate CXCL5 secretion and CXCR2 expression with benign
or malignant proliferative diseases. Indeed, the results of dose-response
experiments conducted as part of the studies reported here demon-
strated that nontransformed N15C6 and BPH-1 cells, as well as trans-
formed androgen-sensitive 22Rv1 and LNCaP cells, although not
transformed androgen-insensitive PC3 cells, responded proliferatively
to exogenous CXCL5. Further testing of two of these cell lines, N15C6
and LNCaP, for percentage of cells exhibiting apoptosis showed that
CXCL5 does not promote an antiapoptotic response, suggesting that
the observed increase in cell number consequent to exposure to CXCL5
is largely a pro-proliferative response.
Of these cell lines examined in this study, only PC3 cells have been
examined by others for a proliferative response to CXCL5 in vitro or
in vivo. Moore et al. [23] reported that treatment of PC3 cells with
100 ng/ml (approximately 12.5 nM) did not elicit a proliferative re-
sponse. These data correlate well with our study, which further dem-
onstrated that PC3 cells did not demonstrate a proliferative response
in vitro to either sub- or suprananomolar levels of exogenously admin-
istered CXCL5. The study by Moore et al. [23] also reported a positive
correlation between the in vivo production of CXCL5 and the expo-
nential growth of PC3 xenografts in vivo, although this effect on
growth may be due to the angiogenic induction of endothelial cell,
rather than PC3 cell, proliferation.
It is unclear why some transformed prostate epithelial cells, e.g.,
LNCaP and 22Rv1, proliferate in response to CXCL5, but others,
e.g., PC3, do not. It is tempting to speculate that the presence or ab-
sence of the androgen receptor in these cells may modulate whether
they can respond proliferatively to CXCL5. However, both N15C6
and BPH-1 cells also responded proliferatively to CXCL5, yet BPH-1
cells do not express the androgen receptor, and N15C6 cells express
only very low levels of this protein [16, and unpublished observa-
tions]. Therefore, it is possible that both androgen-dependent and
-independent mechanisms can be involved in the observed CXCL5-
mediated proliferative response.
Although the proliferative response of N15C6, BPH-1, LNCaP, and
22Rv1 prostate epithelial cells was highly reproducible, it was also rel-
atively modest and, for the most part, confined to subnanomolar levels
of CXCL5. It was clearly specific to CXCL5/CXCR2 interactions, as
both N15C6 and BPH-1 cells failed to proliferate in response to
CXCL5 after pretreatment with antibody against the CXCL5 receptor,
but not antibody against an unrelated chemokine receptor, CXCR4.
The results of these experiments are consistent with those from other
studies conducted in other tumor types, which have shown that
CXCL5 promotes the proliferation of human head and neck squa-
mous carcinoma cells in vitro and in vivo [12], that heterotrophic renal
cell carcinomas fail to proliferate in CXCR2-null mice [24], and that
tumors in the transgenic adenocarcinoma of the mouse prostate model
(TRAMP)/CXCR2–null mice were significantly smaller than those in
TRAMP/CXCR2 +/+ mice and had reduced angiogenesis [25]. Taken
together, these results suggest that CXCL5 stimulates a proliferative
response in both nontransformed and some transformed prostate epi-
thelial cells, thus, may promote abnormal cellular proliferation and fa-
cilitate the development of both benign and malignant proliferative
disease of the prostate.
The observation of abundant and elevated CXCL5 expression in
metastatic compared to primary tumors indicated that CXCL5 may
promote expression of the invasive phenotype required for tumor
metastasis. Indeed, CXCL5 is a chemotaxic agent, and is a key mod-
ulator of immune cell trafficking, especially for granulocytic immune
cells. Experiments reported here show that CXCL5 exerts a strong
and specific chemotactic effect on highly malignant, transformed
PC3 prostate cancer cells, which was substantial enough to draw
the prostate cancer cells through a Matrigel synthetic basement mem-
brane barrier. In contrast, nontransformed N15C6 cells failed to mi-
grate through the Matrigel in response to the same concentration of
CXCL5. Previous studies by Reiland et al. [26] showed that PC3
cells migrated through the reconstituted basement membrane in re-
sponse to 36 nM interleukin-8, another proangiogenic CXC-type
chemokine, and that this response was CXCR2-dependent. Another
study reported by Miyazaki et al. [12] showed that RNA interference
of the CXCL5 transcript reduced the ability of head and neck squa-
mous carcinoma cells to migrate and invade through the Matrigel
in vitro. Together, these studies suggest that CXCL5 may promote
metastasis in multiple tumor types in a CXCR2-dependent manner.
Our laboratory recently reported that subnanomolar levels of another
chemokine, CXCL12, stimulated intracellular signaling through both
MAPK (specifically, MEK/ERK) and PI3K (specifically, NF-κB)
pathways associated with cellular proliferation [4,5]. The current
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study shows that CXCL5 also signals through these pathways, as well
as through the JAK/STAT pathway. In contrast to CXCL12, however,
CXCL5 stimulates ERK phosphorylation in both nontransformed
N15C6 and transformed LNCaP cells, as well as STAT3 activation
in N15C6 cells. Both MAPK-dependent and -independent mecha-
nisms have been shown to activate the transcription factor, ELK-1,
which in turn can activate the promoters of multiple genes containing
serum response elements (e.g., EGR1) or ternary complex factor bind-
ing sites [27–31]. Data reported here show that CXCL5 stimulates the
transcription of EGR1 by both nontransformed N15C6 and trans-
formed LNCaP cells. The observation of similarities, as well as differ-
ences, between intracellular signaling events elicited by CXC-type
chemokines raises the possibility that these chemokines may use both
common and unique cellular mechanisms to induce similar phenotypic
responses, e.g., proliferation, migration/invasion, and gene transcrip-
tion, in prostate cancer cells. If so, the responses of benign or malignant
prostate epithelial cells to endogenously produced (CXCL5) or exoge-
nously produced (CXCL12) chemokines may be the result of a com-
plex interplay between costimulated and differentially stimulated
signaling pathways.
In addition to the expression and biologic activities of CXCL5 in
connection with tumor development, CXCL5 expression by epithelial
cells has been frequently observed in conjunction with inflammatory
responses. For example, CXCL5 protein expression by the intestinal
mucosa has been observed in association with inflammatory conditions
such as Crohn disease, ulcerative colitis, and acute appendicitis, and by
the exocrine tissue of the pancreas associated with chronic pancreatitis
[9]. Our studies reported here show that the CXCL5 protein expres-
sion levels are concurrent with tumor progression and are coincident
with the presence of granulocytic inflammatory cells. Inflammatory in-
filtrate in the prostate coincident with benign prostatic enlargement
and prostate cancer has been frequently observed, provoking intense
interest in the potential role of inflammatory mediators in the etiology
of both diseases [32–37]. The studies reported here for the inflam-
matory mediator, CXCL5, are consistent with these observations. In
addition, these and other studies show that CXCL5 promotes the pro-
liferation and metastasis of both nontransformed and transformed cells
in vitro and in vivo. Taken together, these data provide rationale for
exploring potential functional links between inflammatory mediators
and the development of benign hypertrophic or malignant neoplastic
proliferative disease in the prostate.
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